Details
Title
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
Author
Lim Byungho 1
; Yoo Dabin 1 ; Chun Younghwa 2 ; Go Areum 2 ; Kyung-Jin, Cho 1 ; Choi Daeun 1 ; Jung, Myoung Eun 1 ; Lee Ha Young 2 ; Boohaker, Rebecca J 3 ; Lee, Jin Soo 4 ; Jung DooYoung 4 ; Choi Gildon 1
1 Korea Research Institute of Chemical Technology, Research Center for Drug Discovery Technology, Daejeon, Republic of Korea (GRID:grid.29869.3c) (ISNI:0000 0001 2296 8192)
2 Pinotbio, Inc, Suwon, Republic of Korea (GRID:grid.29869.3c)
3 Division of Drug Discovery, Southern Research, Birmingham, USA (GRID:grid.454225.0) (ISNI:0000 0004 0376 8349)
4 Pinotbio, Inc, Suwon, Republic of Korea (GRID:grid.454225.0)
; Yoo Dabin 1 ; Chun Younghwa 2 ; Go Areum 2 ; Kyung-Jin, Cho 1 ; Choi Daeun 1 ; Jung, Myoung Eun 1 ; Lee Ha Young 2 ; Boohaker, Rebecca J 3 ; Lee, Jin Soo 4 ; Jung DooYoung 4 ; Choi Gildon 1
1 Korea Research Institute of Chemical Technology, Research Center for Drug Discovery Technology, Daejeon, Republic of Korea (GRID:grid.29869.3c) (ISNI:0000 0001 2296 8192)
2 Pinotbio, Inc, Suwon, Republic of Korea (GRID:grid.29869.3c)
3 Division of Drug Discovery, Southern Research, Birmingham, USA (GRID:grid.454225.0) (ISNI:0000 0004 0376 8349)
4 Pinotbio, Inc, Suwon, Republic of Korea (GRID:grid.454225.0)
Publication year
2022
Publication date
Apr 2022
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2649212926
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.